Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENZONATATE vs AMMONIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.
Symptomatic relief of cough
Treatment of metabolic alkalosis,Urinary acidification to enhance excretion of weak bases in poisoning,Expectorant (off-label)
100 mg to 200 mg orally three times daily as needed for cough.
For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 8-12 hours in normal renal function; prolonged in renal impairment (up to 30 hours) due to reliance on renal acid excretion.
Metabolized by plasma esterases (including pseudocholinesterase) to tetracaine and other metabolites.
Ammonium chloride is metabolized in the liver via the urea cycle, where ammonium is converted to urea, consuming bicarbonate and generating hydrogen ions.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Renal: >99% as ammonium ion (NH4+) and chloride (Cl-), with acid excretion via conversion of NH4+ to urea in liver; minimal biliary/fecal.
Approximately 75–85% bound primarily to albumin.
<10% bound to plasma proteins (primarily albumin).
Approximately 3.5 L/kg, indicating extensive tissue distribution.
Approximately 0.3-0.5 L/kg, distributing mainly in extracellular fluid; minimal intracellular penetration.
Oral: Estimated 20–30% due to extensive first-pass metabolism.
Oral: 70-80% (subject to first-pass hepatic conversion of NH4+ to urea); intravenous: 100%.
No specific dosage adjustment is recommended for renal impairment per manufacturer; however, caution and monitoring are advised.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 50% and monitor for acidosis. For GFR >60 m L/min: no adjustment necessary.
No specific dosage adjustment is recommended for hepatic impairment per manufacturer; however, caution is advised.
No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to risk of encephalopathy.
Safety and efficacy have not been established in children under 10 years of age. For children ≥10 years, adult dosing can be considered.
For metabolic alkalosis: 50-100 mg/kg orally every 6-8 hours, not to exceed 6 g/day. Intravenous: 2-3 mmol/kg over 4-6 hours, repeat based on blood p H.
Elderly patients may be more sensitive to CNS effects; start at lower end of dosing range (100 mg three times daily) and monitor carefully.
Start at low end of dosing range; monitor renal function and electrolytes closely due to age-related decline in GFR.
None
None.
Severe allergic reactions (e.g., bronchospasm, laryngospasm, cardiovascular collapse) have been reported, especially with chewing or sucking capsules.,Capsules must be swallowed whole to avoid oral mucosal anesthesia and choking hazard.,Use with caution in patients with hypersensitivity to ester-type local anesthetics.,Safety and efficacy in children <10 years not established.
May cause metabolic acidosis, hyperammonemia in hepatic impairment, and electrolyte disturbances. Use with caution in patients with renal or hepatic disease, pulmonary insufficiency, or cardiac edema.
Hypersensitivity to benzonatate or related compounds (e.g., tetracaine, procaine)
Severe hepatic or renal impairment, primary respiratory acidosis, and patients with uremia or high serum bicarbonate levels.
No significant food interactions. The manufacturer does not list any specific dietary restrictions, but alcohol may enhance central nervous system side effects such as drowsiness.
Avoid excessive consumption of alkaline foods (e.g., dairy products, fruits) as they may counteract the acidifying effect. Maintain a consistent diet to avoid fluctuations in acid-base balance.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near term. Second and third trimesters: Avoid use due to potential for neonatal apnea and withdrawal; benzonatate is a local anesthetic with CNS depressant effects.
Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, including fetal acidosis and altered fetal p H homeostasis, particularly in the second and third trimesters. No specific trimester-specific risks are well-documented.
No data on excretion in human milk; M/P ratio unknown. Benzonatate and its metabolites may be present in breast milk. Caution advised due to potential for infant CNS depression and apnea. Consider benefit of breastfeeding vs risk of drug exposure.
Ammonium chloride is excreted into breast milk in small amounts. The M/P ratio is not well-established. At therapeutic doses, exposure to the nursing infant is likely low and not expected to cause adverse effects. Caution is advised with high doses due to potential for maternal acidosis and subsequent infant effects. Consider monitoring infant for signs of acidosis if maternal therapy is prolonged or high-dose.
No pharmacokinetic studies in pregnancy. Dose adjustments not established. Use lowest effective dose if necessary. Avoid in third trimester due to neonatal risk. Increased plasma volume may reduce drug levels, but lack of data prevents formal dose adjustment recommendations.
Pregnancy increases plasma volume and renal clearance, which may reduce the effectiveness of ammonium chloride as an acidifying agent. Higher doses may be required to achieve therapeutic effect, but this must be balanced against the risk of acidosis. No standard dose-adjustment guidelines exist; dosing should be individualized based on maternal acid-base monitoring. Avoid excessive doses that could cause severe acidosis.
Benzonatate is a peripherally acting antitussive that anesthetizes stretch receptors in the respiratory tract. Onset of action is within 15-20 minutes and lasts 3-8 hours. Capsules must be swallowed whole; chewing or sucking can cause oropharyngeal anesthesia and choking hazard. Use with caution in patients with a history of drug allergy to tetracaine or other ester-type anesthetics. It is contraindicated in children under 10 years due to increased risk of adverse effects. Overdose can cause seizures, cardiac arrest, and death; treatment is supportive with no specific antidote.
Ammonium chloride is used as a systemic acidifying agent to treat metabolic alkalosis. Monitor serum electrolytes and acid-base status closely during therapy. Avoid in severe hepatic or renal impairment. Use with caution in patients with respiratory acidosis.
Swallow the capsule whole; do not chew, suck, or crush it, as this can cause numbness in your mouth or throat and increase risk of choking.,Take the medication exactly as prescribed; do not take more than directed.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Contact your doctor if your cough persists for more than 5 days, or if it is accompanied by fever, rash, or persistent headache.,Keep out of reach of children; accidental ingestion can be fatal in children under 10.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed. Do not exceed the recommended dose.,Notify your doctor if you experience nausea, vomiting, confusion, or rapid breathing.,Avoid taking with antacids or alkalinizing agents as they may reduce effectiveness.,Stay hydrated unless otherwise directed by your physician.,Inform your healthcare provider of all medications you are taking, especially diuretics or corticosteroids.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENZONATATE vs AMMONIUM CHLORIDE, answered by our medical review team.
BENZONATATE is a Antitussive that works by Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.. AMMONIUM CHLORIDE is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent. It dissociates to ammonium and chloride ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which lower blood and urinary p H. It also increases chloride concentration, promoting excretion of bicarbonate and other bases.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENZONATATE and AMMONIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENZONATATE is: 100 mg to 200 mg orally three times daily as needed for cough.. The standard adult dose of AMMONIUM CHLORIDE is: For metabolic alkalosis: 1-2 g orally 3-4 times daily; or 1 g (as 2 mmol/kg) intravenously over 4-6 hours, repeat as needed based on blood gas analysis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENZONATATE and AMMONIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENZONATATE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near te. AMMONIUM CHLORIDE is classified as Category C. Ammonium chloride is not associated with major human teratogenicity. However, due to its potential to induce metabolic acidosis, high doses may pose theoretical fetal risks, includ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.